Reply to the Letter to the Editor in response to “Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis”

European Journal of NeurologyVolume 30, Issue 1 p. 283-284 LETTER TO THE EDITOR Reply to the Letter to the Editor in response to “Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis” Nilo Riva, Corresponding Author Nilo Riva [email protected] orcid.org/0000-0002-0513-9517 Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy Neurology Unit and Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy Correspondence Nilo Riva, Experimental Neuropathology Unit, Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy. Email: [email protected]Search for more papers by this authorAngelo Quattrini, Angelo Quattrini Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, ItalySearch for more papers by this author Nilo Riva, Corresponding Author Nilo Riva [email protected] orcid.org/0000-0002-0513-9517 Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy Neurology Unit and Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy Correspondence Nilo Riva, Experimental Neuropathology Unit, Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milan, Italy. Email: [email protected]Search for more papers by this authorAngelo Quattrini, Angelo Quattrini Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, ItalySearch for more papers by this author First published: 29 September 2022 https://doi.org/10.1111/ene.15586Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Falzone YM, Domi T, Mandelli A, et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022; 29(7): 1930- 1939. doi:10.1111/ene.15321 2Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019; 32(5): 747- 757. doi:10.1097/WCO.0000000000000744 3Riva N, Gentile F, Cerri F, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022; 145(1): 276- 284. doi:10.1093/brain/awab285 4Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018; 55(10): 7789- 7801. doi:10.1007/s12035-018-0947-6 5Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018; 18(1): 90. doi:10.1186/s12883-018-1091-7 6Conti E, Sala G, Diamanti S, et al. Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Sci Rep. 2021; 11(1): 1978. doi:10.1038/s41598-021-81,599-5 7Sferruzza G, Bosco L, Falzone YM, et al. Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study. Amyotroph Lateral Scler Frontotemporal Degener. 2022; 23(5–6): 446- 457. doi:10.1080/21678421.2021.2007952 8Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020; 383(2): 109- 119. doi:10.1056/NEJMoa2003715 9Sugimoto K, Hiwasa T, Shibuya K, et al. Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. J Neuroimmunol. 2018; 325: 54- 60. doi:10.1016/j.jneuroim.2018.09.013 10Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75 ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017; 88(12): 1137- 1143. doi:10.1212/WNL.0000000000003741 11Lunetta C, Lizio A, Gerardi F, et al. Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. J Neurol. 2020; 267(12): 3609- 3616. doi:10.1007/s00415-020-10047-7 Volume30, Issue1January 2023Pages 283-284 ReferencesRelatedInformation